ss
   asdf
gfgdfg   
Publications


Dendritic Cell Targeted Adenovirus Vaccines

  • Wilkinson-Ryan I, Kim J, Kim S, Ak F, Dodson L, Colonna M, Powell M, Mutch D, Spitzer D, Hansen T, Goedegebuure SP, Curiel D, Hawkins W. Incorporation of porcine adenovirus 4 fiber protein enhances infectivity of adenovirus vector on dendritic cells: implications for immune-mediated cancer therapy. PLoS One. 2015 May 1;10(5):e0125851. PMID: 25933160
  • Williams BJ, Bhatia S, Adams LK, Boling S, Carroll JL, Li XL, Rogers DL, Korokhov N, Kovesdi I, Pereboev AV, Curiel DT, Mathis JM. Dendritic cell based PSMA immunotherapy for prostate cancer using a CD40-targeted adenovirus vector. PLoS One. 2012;7(10):e46981. PMID: 23056548
  • Hangalapura BN, Timares L, Oosterhoff D, Scheper RJ, Curiel DT, de Gruijl TD. CD40-targeted adenoviral cancer vaccines: the long and winding road to the clinic. J Gene Med. 2012 Jun;14(6):416-27. PMID: 22228547
  • Hangalapura BN, Oosterhoff D, de Groot J, Boon L, Tüting T, van den Eertwegh AJ, Gerritsen WR, van Beusechem VW, Pereboev A, Curiel DT, Scheper RJ, de Gruijl TD. Potent antitumor immunity generated by a CD40-targeted adenoviral vaccine. Cancer Res. 2011 Sep 1;71(17):5827-37. PMID: 21747119
  • Hangalapura BN, Oosterhoff D, Gupta T, de Groot J, Wijnands PG, van Beusechem VW, den Haan J, Tüting T, van den Eertwegh AJ, Curiel DT, Scheper RJ, de Gruijl TD. Delivery route, MyD88 signaling and cross-priming events determine the anti-tumor efficacy of an adenovirus based melanoma vaccine. Vaccine. 2011 Mar 9;29(12):2313-21. PMID: 21272606
  • Hangalapura BN, Oosterhoff D, Aggarwal S, Wijnands PG, van de Ven R, Santegoets SJ, van den Tol MP, Hooijberg E, Pereboev A, van den Eertwegh AJ, Curiel DT, Scheper RJ, de Gruijl TD. Selective transduction of dendritic cells in human lymph nodes and superior induction of high-avidity melanoma-reactive cytotoxic T cells by a CD40-targeted adenovirus. J Immunother. 2010 Sep;33(7):706-15. PMID: 20664356
  • van de Ven R, Lindenberg JJ, Oosterhoff D, van den Tol MP, Rosalia RA, Murakami M, Everts M, Scheffer GL, Scheper RJ, de Gruijl TD, Curiel DT. Selective transduction of mature DC in human skin and lymph nodes by CD80/CD86-targeted fiber-modified adenovirus-5/3. J Immunother. 2009 Nov-Dec;32(9):895-906. PMID: 19816192
  • Thacker EE, Nakayama M, Smith BF, Bird RC, Muminova Z, Strong TV, Timares L, Korokhov N, O'Neill AM, de Gruijl TD, Glasgow JN, Tani K, Curiel DT. A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo. Vaccine. 2009 Nov 23;27(50):7116-24. PMID: 19786146

SDAb Targeted CRAd

  • Dmitriev IP, Kashentseva EA, Kim KH, Matthews QL, Krieger SS, Parry JJ, Nguyen KN, Akers WJ, Achilefu S, Rogers BE, Alvarez RD, Curiel DT. Monitoring of biodistribution and persistence of conditionally replicative adenovirus in a murine model of ovarian cancer using capsid-incorporated mCherry and expression of human somatostatin receptor subtype 2 gene. Mol Imaging. 2014;13. PMID: 25249483
  • Kaliberov SA, Kaliberova LN, Buchsbaum DJ, Curiel DT. Experimental virotherapy of chemoresistant pancreatic carcinoma using infectivity-enhanced fiber-mosaic oncolytic adenovirus. Cancer Gene Ther. 2014 Jul;21(7):264-74. PMID: 24903014
  • Kim KH, Dmitriev IP, Saddekni S, Kashentseva EA, Harris RD, Aurigemma R, Bae S, Singh KP, Siegal GP, Curiel DT, Alvarez RD. A phase I clinical trial of Ad5/3-Δ24, a novel serotype-chimeric, infectivity-enhanced, conditionally-replicative adenovirus (CRAd), in patients with recurrent ovarian cancer. Gynecol Oncol. 2013 Sep;130(3):518-24. PMID: 23756180
  • Viale DL, Cafferata EG, Gould D, Rotondaro C, Chernajovsky Y, Curiel DT, Podhajcer OL, Lopez MV. Therapeutic improvement of a stroma-targeted CRAd by incorporating motives responsive to the melanoma microenvironment. J Invest Dermatol. 2013 Nov;133(11):2576-84. PMID: 23604101
  • Lopez MV, Rivera AA, Viale DL, Benedetti L, Cuneo N, Kimball KJ, Wang M, Douglas JT, Zhu ZB, Bravo AI, Gidekel M, Alvarez RD, Curiel DT, Podhajcer OL.  A tumor-stroma targeted oncolytic adenovirus replicated in human ovary cancer samples and inhibited growth of disseminated solid tumors in mice. Mol Ther. 2012 Dec;20(12):2222-33. PMID: 22948673
  • Kim KH, Ryan MJ, Estep JE, Miniard BM, Rudge TL, Peggins JO, Broadt TL, Wang M, Preuss MA, Siegal GP, Hemminki A, Harris RD, Aurigemma R, Curiel DT, Alvarez RD. A new generation of serotype chimeric infectivity-enhanced conditionally replicative adenovirals: the safety profile of ad5/3-Δ24 in advance of a phase I clinical trial in ovarian cancer patients. Hum Gene Ther. 2011 Jul;22(7):821-8. PMID: 21171861
  • Kimball KJ, Preuss MA, Barnes MN, Wang M, Siegal GP, Wan W, Kuo H, Saddekni S, Stockard CR, Grizzle WE, Harris RD, Aurigemma R, Curiel DT, Alvarez RD. A phase I study of a tropism-modified conditionally replicative adenovirus for recurrent malignant gynecologic diseases. Clin Cancer Res. 2010 Nov 1;16(21):5277-87. PMID: 20978148
  • Tsuruta Y, Pereboeva L, Breidenbach M, Rein DT, Wang M, Alvarez RD, Siegal GP, Dent P, Fisher PB, Curiel DT. A fiber-modified mesothelin promoter-based conditionally replicating adenovirus for treatment of ovarian cancer. Clin Cancer Res. 2008 Jun 1;14(11):3582-8. PMID: 18519792
  • van Erp E, Kaliberova L, Kaliberov SA, Curiel DT. Retargeted oncolytic adenovirus displaying a single variable domain of camelid heavy-chain-only antibody in a fiber protein. Molecular Therapy — Oncolytics (2015) 2, 15001

One Health

  • Thacker EE, Nakayama M, Smith BF, Bird RC, Muminova Z, Strong TV, Timares L, Korokhov N, O'Neill AM, de Gruijl TD, Glasgow JN, Tani K, Curiel DT. A genetically engineered adenovirus vector targeted to CD40 mediates transduction of canine dendritic cells and promotes antigen-specific immune responses in vivo. Vaccine. 2009 Nov 23;27(50):7116-24. PMID: 19786146
  • Le LP, Li J, Ternovoi VV, Siegal GP, Curiel DT. Fluorescently tagged canine adenovirus via modification with protein IX-enhanced green fluorescent protein. J Gen Virol. 2005 Dec;86(Pt 12):3201-8. PMID: 16298964
  • Le LP, Rivera AA, Glasgow JN, Ternovoi VV, Wu H, Wang M, Smith BF, Siegal GP, Curiel DT. Infectivity enhancement for adenoviral transduction of canine osteosarcoma cells. Gene Ther. 2006 Mar;13(5):389-99. PMID: 16292351
  • Stoff-Khalili MA, Stoff A, Rivera AA, Mathis JM, Everts M, Wang M, Kawakami Y, Waehler R, Mathews QL, Yamamoto M, Rocconi RP, Siegal GP, Richter DF, Dall P, Zhu ZB, Curiel DT. Gene transfer to carcinoma of the breast with fiber-modified adenoviral vectors in a tissue slice model system. Cancer Biol Ther. 2005 Nov;4(11):1203-10. PMID: 16177567
  • Stoff-Khalili MA, Rivera AA, Glasgow JN, Le LP, Stoff A, Everts M, Tsuruta Y, Kawakami Y, Bauerschmitz GJ, Mathis JM, Pereboeva L, Seigal GP, Dall P, Curiel DT. A human adenoviral vector with a chimeric fiber from canine adenovirus type 1 results in novel expanded tropism for cancer gene therapy. Gene Ther. 2005 Dec;12(23):1696-706. PMID: 16034451
  • Glasgow JN, Kremer EJ, Hemminki A, Siegal GP, Douglas JT, Curiel DT. An adenovirus vector with a chimeric fiber derived from canine adenovirus type 2 displays novel tropism. Virology. 2004 Jun 20;324(1):103-16. PMID: 15183058
  • Hemminki A, Kanerva A, Kremer EJ, Bauerschmitz GJ, Smith BF, Liu B, Wang M, Desmond RA, Keriel A, Barnett B, Baker HJ, Siegal GP, Curiel DT. A canine conditionally replicating adenovirus for evaluating oncolytic virotherapy in a syngeneic animal model. Mol Ther. 2003 Feb;7(2):163-73. PMID: 12597904

Anti-angiogenesis Gene Therapy

  • Lu ZH, Kaliberov S, Zhang J, Muz B, Azab AK, Sohn RE, Kaliberova L, Du Y, Curiel DT, Arbeit JM.The myeloid-binding peptide adenoviral vector enables multi-organ vascular endothelial gene targeting. Lab Invest. 2014 Aug;94(8):881-92. PMID: 24955893
  • Kaliberov SA, Kaliberova LN, Buggio M, Tremblay JM, Shoemaker CB, Curiel DT. Adenoviral targeting using genetically incorporated camelid single variable domains. Lab Invest. 2014 Aug;94(8):893-905. PMID: 24933423
  • Lu ZH, Kaliberov S, Sohn RE, Kaliberova L, Curiel DT, Arbeit JM. Transcriptional targeting of primary and metastatic tumor neovasculature by an adenoviral type 5 roundabout4 vector in mice. PLoS One. 2013 Dec 23;8(12):e83933. PMID: 24376772
  • Kaliberov SA, Kaliberova LN, Hong Lu Z, Preuss MA, Barnes JA, Stockard CR, Grizzle WE, Arbeit JM, Curiel DT. Retargeting of gene expression using endothelium specific hexon modified adenoviral vector. Virology. 2013 Dec;447(1-2):312-25. PMID: 24210128
  • Kim JW, Glasgow JN, Nakayama M, Ak F, Ugai H, Curiel DT. An adenovirus vector incorporating carbohydrate binding domains utilizes glycans for gene transfer. PLoS One. 2013;8(2):e55533. PMID: 23383334
  • Alberti MO, Deshane JS, Chaplin DD, Pereboeva L, Curiel DT, Roth JC.A myeloid cell-binding adenovirus efficiently targets gene transfer to the lung and escapes liver tropism.Gene Ther. 2013 Jul;20(7):733-41. PMID: 23171918
  • Alberti MO, Roth JC, Ismail M, Tsuruta Y, Abraham E, Pereboeva L, Gerson SL, Curiel DT. Derivation of a myeloid cell-binding adenovirus for gene therapy of inflammation. PLoS One. 2012;7(5):e37812. PMID: 22624065
  • Murakami M, Ugai H, Wang M, Belousova N, Dent P, Fisher PB, Glasgow JN, Everts M, Curiel DT. An adenoviral vector expressing human adenovirus 5 and 3 fiber proteins for targeting heterogeneous cell populations. Virology. 2010 Nov 25;407(2):196-205. PMID: 20828776